California, USA-based Vivus. (Nasdaq: VVUS) says that it has entered into an asset purchase agreement with Swedish drugmaker Meda AB (MEDAA: SS) for MUSE, transurethral alprostadil, for the treatment of erectile dysfunction (ED), for around $23.5 million.
Under the deal, Meda will acquire the MUSE assets including the US and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey. As part of the transaction, the existing Vivus employees that are MUSE dedicated, including the field sales force, are expected to join Meda. Vivus will retain all of the liabilities associated with the pre-closing operations of the MUSE business.
Deal will allow Vivus to focus on Qnexa and avanafil
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze